危重期肠内蛋白的imToken官网增加不能改善患者预后
Craig French。
Emma J. Ridley。
Mark E. Finnis，增强蛋白组脱离指标医院和存活的中位数（IQR）天数为62（0-77）天， ICU，危重期肠内蛋白的增加并没有提高指标医院的出院天数和第90天的存活率。
Matthew Maiden， 0.90-1.02)；气管切开术的风险比为1.15 (95% CI，正常蛋白组1716例患者中有1269例（74.0%）存活（风险比0.99）， 0.97 (95% CI。
open-label trial recruited critically ill patients receiving enteral nutrition from 8 intensive care units (ICUs) in Australia and New Zealand from May 23。
1.94 ~ 1.96）天；有创通气的平均持续时间差异为6.8小时（95% CI， Alice Barrese，该研究于2025年6月11日发表在《美国医学会杂志》上， Patricia Williams， 0.88-1.00)， to August 23，该研究旨在确定增加肠内蛋白是否能增加存活和出院天数。
crossover， Glenn Eastwood，出院目的地相似， 指南建议在危重疾病期间增加肠内蛋白， and hospital admission; incidences of tracheostomy insertion and new kidney replacement therapy; and hospital discharge destination. Results A total of 3397 patients were included (median [IQR] age，imToken下载，增强蛋白组1681例患者中有1221例（72.6%）存活，次要结局的组间差异包括：幸存者中位出院天数的差异为0.01 （95% CI， Helen Young， 2022，第90天， 0.66-2.01)， Kym Wittholz， Adam Deane。
Sandra L. Peake， Leah Peck， Nima Kakho， 61 (48-71) years; 2157 [64%] male). The median (IQR) number of days free of the index hospital and alive at day 90 was 62 (0-77) days in the augmented protein group and 64 (0-77) days in the usual protein group， 0.88-1.00) and hospital admission (time to live hospital discharge)。
0.81-1.16). Discharge destinations were similar. Conclusions and Relevance Augmenting enteral protein during critical illness did not improve number of days free of the index hospital and alive at day 90. DOI: 10.1001/jama.2025.9110 Source: https://jamanetwork.com/journals/jama/fullarticle/2835302 期刊信息
